Individuals with DMD share common features of disease progression, but the pace of that progression and the muscles most degraded are influenced by genotype, treatment exposure (particularly timing of corticosteroid initiation), and adherence to current multidisciplinary care. standards significantly influence progression trajectories.
Videos: Rare Takes
In this video series, Muscular Dystrophy experts discuss important topics related to diagnosing, managing, and treating the disease, from the importance of early diagnosis to collaboration with patients, families, and other providers.
Latest News & Research
In this guide
Individuals with DMD share common features of disease progression, but the pace of that progression and the muscles most degraded are influenced by genotype, treatment exposure (particularly timing of corticosteroid initiation), and adherence to current multidisciplinary care. standards significantly influence progression trajectories.
Individuals with DMD share common features of disease progression, but the pace of that progression and the muscles most degraded are influenced by genotype, treatment exposure (particularly timing of corticosteroid initiation), and adherence to current multidisciplinary care. standards significantly influence progression trajectories.
Individuals with DMD share common features of disease progression, but the pace of that progression and the muscles most degraded are influenced by genotype, treatment exposure (particularly timing of corticosteroid initiation), and adherence to current multidisciplinary care. standards significantly influence progression trajectories.
Individuals with DMD share common features of disease progression, but the pace of that progression and the muscles most degraded are influenced by genotype, treatment exposure (particularly timing of corticosteroid initiation), and adherence to current multidisciplinary care. standards significantly influence progression trajectories.
Individuals with DMD share common features of disease progression, but the pace of that progression and the muscles most degraded are influenced by genotype, treatment exposure (particularly timing of corticosteroid initiation), and adherence to current multidisciplinary care. standards significantly influence progression trajectories.
Individuals with DMD share common features of disease progression, but the pace of that progression and the muscles most degraded are influenced by genotype, treatment exposure (particularly timing of corticosteroid initiation), and adherence to current multidisciplinary care. standards significantly influence progression trajectories.
Individuals with DMD share common features of disease progression, but the pace of that progression and the muscles most degraded are influenced by genotype, treatment exposure (particularly timing of corticosteroid initiation), and adherence to current multidisciplinary care. standards significantly influence progression trajectories.